Keyword: Shanghai Pharmaceutical
Astellas plots 600 job cuts in Japan; GSK's infectious disease lead launches a Chinese biotech; Sun Pharma's Zytiga rival wins the FDA's blessing.
Takeda-Zinfandel dropped an Alzheimer’s study; Shanghai Pharma will open an R&D site in the U.S.; NextCODE CEO talked about company plans.
Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
Amgen inked a biosim deal with Simcere, Gilead won a Chinese nod for Sovaldi, and Shanghai Pharma is in talks to buy part of Alvogen.
Amid a wave of pricing pressure and consolidation in the generics industry, another sale is brewing.
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.
Buyout target Stada is rolling out cost-cutting measures and new guidance in an attempt to bring in larger bids.
Fosun Pharma and Shanghai Pharma were said to be interested in buying Stada, Daiichi struck a pain drug R&D deal with Heptares, and Sun Pharma unloads one FDA ban.